Ab182801-5mg 5mg现货 原价:¥2,399.90 +- Ab182801-10mg 10mg期货 原价:¥3,899.90 +- Skip to the end of the images gallery Skip to the beginning of the images gallery 基本信息 产品名称Toripalimab (anti-PD-1), 程序性细胞死亡蛋白 1 拮抗剂 ...
Ab182979-5mg 5mg现货 原价:¥7,499.90 +- Ab182979-10mg 10mg期货 原价:¥11,999.90 +- Skip to the end of the images gallery Skip to the beginning of the images gallery 基本信息 产品名称Rosnilimab (anti-PD-1) 英文别名CD279 antigen antibody | hPD 1 antibody | hPD l antibody | hPD-...
[0042] 本公开内容在一方面提供一种PD‑1蛋白质结合剂,其中根据所述本公开内容的 PD‑1蛋白质结合剂为选自如下的抗体或其抗原结合片段:骆驼化单域抗体、双抗体、F (ab) 、Fab、Fab、Fv、单链可变区片段(single chain variable fragment,scFv)、scFV二 2 聚体、二价单链可变区片段 (bivalent single‑...
Oncolytic virotherapy was found to increase CD8+ T cell infiltration in the injected lesions and improve the efficacy of anti-PD-1 ab in a phase 1b trial. We hypothesized that intratumoral oncolytic virus injection for liver metastasis in melanoma combined with systemic anti-PD-1 therapy might ...
之前的研究表明，如果PD-L1表达大于50％，患者就可以选择PD-1抑制剂单药治疗，从而免于接受化疗。然而，...
This phase 1b/2 study investigated the safety and efficacy of sintilimab, a fully human anti-PD-1 antibody, plus chidamide, an oral subtype-selective histone deacetylase inhibitor in 38 patients with RR-ENKTL. Expected objective response rate (ORR) of combination treatment was 80%. Patients ...
Exclusion criteria included ocular or unknown primary melanoma, distant metastatic disease or previous use of anti PD-1 ab. Pts received toripalimab 3 mg/kg Q2W plus axitinib 5 mg BID for 8 weeks as neoadjuvant therapy, then surgery and the adjuvant toripalimab 3 mg/kg Q2W starting 2±1...
γδ T-cell adoptive immunotherapy over time in xenogeneic solid tumor mice treated with 1× PBS (Blank), γδ T cells, nonsense-vector γδ T cells (Lv), PD-1-Ab-secreting γδ T cells (Lv-PD1) or γδ T cells with anti-PD-1 Ab (γδ T + αPD-1 Ab) (n = 10...
2021年12月23日,北京大学生物医学前沿创新中心(BIOPIC)、生命科学学院、北京未来基因诊断高精尖创新中心(ICG)张泽民课题组联合301医院韩为东课题组在Nature Cancer上发表了题为Temporal single-cell tracing reveals clonal revival and expans...
关键字:Avelumab;阿维鲁单抗;1537032-82-8;B7H1, PD-L1;PDCD1LG1; 公司简介 武汉佰乐博生物(Biolab Reagents)由五位毕业于华中科技大学,华中农业大学,武汉大学等知名高校,且具有二十年工作经验的生命科学领域顶级研究者创立于2021年,凭借丰富的产品开发经验,利用全球领先的技术平台,引进和整合全球高品质的蛋白、抗...